When Christina Ackermann came on board in August 2016, Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, was a distressed, if not sinking, ship. She spent her first week with outside counsel studying a flood of legal and regulatory problems, and assessing the pharmaceutical company’s legal strengths and weaknesses.

Helping to right the ship has taught “me more in the last two years than I learned in the previous 15 at Novartis,” the veteran in-house counsel, who is executive vice president and general counsel, told Corporate Counsel in a recent interview. “Novartis is a fabulous company,” she added, “but the learning curve here, with the challenges we had, has just been, well, fun.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]